Acute Care Therapeutics for Surgical Settings

Baudax Bio is a pharmaceutical company focused on developing and commercializing innovative products for acute care settings.

About Baudax Bio

We are committed to bringing meaningful therapeutic options to patients, healthcare providers, and payers.  We currently have multiple therapeutic candidates across early, mid and late-stage clinical development, including a FDA approved non-opioid therapy for use in the acute care setting.

About Us

Our Innovative Portfolio & Pipeline

On February 20, 2020, the FDA approved ANJESO (meloxicam) injection, for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.  Our product pipeline contains valuable therapeutic candidates for patients and healthcare providers in acute care settings.

ANJESO (meloxicam) injection

Product Portfolio

Latest News

Baudax Bio to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit

View Press Release

Baudax Bio to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit

View Press Release

Baudax Bio Awarded Group Purchasing Agreement with Premier Inc. for ANJESO®

View Press Release

Baudax Bio Appoints Arnold Baskies, M.D. and Andrew Drechsler to Board of Directors

View Press Release

Baudax Bio Reports Second Quarter 2020 Financial Results

View Press Release

Baudax Bio to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020

View Press Release

Baudax Bio Secures Permanent J-Code (J1738) for ANJESO® from Centers for Medicare and Medicaid Services

View Press Release

Baudax Bio Announces Presentation of New Phase IIIb ANJESO® Data at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Meeting

View Press Release

Baudax Bio Secures Pharmacy Supplier Agreement with Vizient Inc. for ANJESO®

View Press Release

Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

View Press Release

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today